SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

Aytu BioPharma Is Maintained at Buy by Ascendiant Capital

Ratings actions from Benzinga: GMT) Aytu BioPharma Price Target Raised to $15.00/Share From $14.50 by Ascendiant CapitalRatings actions from Benzinga

AYTU

Related stories